Later Rise in Bile Acids Tied to Higher Stillbirth Risk in Severe Intrahepatic Cholestasis of Pregnancy: Study Shows

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2026-01-15 14:30 GMT   |   Update On 2026-01-15 14:30 GMT
Advertisement

UK: A new study published in the European Journal of Obstetrics & Gynecology and Reproductive Biology has drawn attention to the timing of bile acid elevation in women with intrahepatic cholestasis of pregnancy (ICP) and its association with stillbirth.

The research, led by Agata Majewska from the Department of Women and Children’s Health, King’s College London, and colleagues, found that the gestational age at which bile acids reach severely elevated levels (≥100 µmol/L) plays a crucial role in determining stillbirth risk.
Advertisement
The observational cohort study included 198 women with singleton pregnancies and severe ICP, a condition characterized by elevated bile acids and liver dysfunction during pregnancy. Among the participants, 15 pregnancies (7.6%) resulted in stillbirth.
The study revealed the following findings:
  • The risk of stillbirth increased with each advancing week of gestation at which bile acid levels peaked (OR 1.28).
  • Women who developed severe intrahepatic cholestasis of pregnancy (ICP) after 28 weeks faced over a threefold higher risk of stillbirth compared to those with an earlier onset (OR 3.47).
  • Most stillbirths were preceded by a sudden and marked rise in bile acid levels, typically within five days before the event.
  • Once bile acid concentrations reached or exceeded 100 µmol/L, the overall risk of stillbirth did not continue to increase proportionally.
  • The timing of bile acid elevation—rather than the absolute level—was the key factor influencing the likelihood of stillbirth, with later onset or peak levels linked to higher risk.
To determine these associations, the researchers employed logistic regression and compared outcomes based on when bile acid levels first became severely elevated and when they reached their peak. They found that patients who experienced stillbirth generally reached their peak bile acid levels later in pregnancy than those who went on to have live births (p = 0.029).
Majewska and colleagues highlighted that their findings underscore the importance of frequent bile acid monitoring and individualized management strategies. The detection of a rapid bile acid surge late in pregnancy may prompt closer fetal surveillance and inform decisions about optimal timing of delivery.
While the study provides valuable insights, the authors acknowledged certain limitations. The sample included only 15 stillbirth cases, and recruitment was enriched through UK-wide networks and the charity ICP Support, which may have introduced selection bias. Moreover, the observational nature of the research and the lack of standardized bile acid testing intervals limited real-time clinical applicability.
"The study highlights that both the gestational age at onset and at the peak of severe bile acid elevation are key determinants of stillbirth in ICP. Regular bile acid testing and vigilant follow-up may help identify pregnancies at heightened risk, supporting more personalized decisions about the timing of delivery and improving perinatal outcomes," the authors concluded.
Reference: https://www.ejog.org/article/S0301-2115(25)01076-0/fulltext


Tags:    
Article Source : European Journal of Obstetrics & Gynecology and Reproductive Biology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News